Pneumococcal conjugate vaccines in pediatrics, its impact on Public Health

Streptococcus pneumoniae (also known as pneumococcus) is part of the natural bacterial flora of the nasal and pharyngeal mucosa, colonizes mainly the nasopharynx, and causes this carriage to precede pneumococcal disease, thus becoming the main source of propagation among people, especially in childr...

Full description

Saved in:
Bibliographic Details
Published in:Andes pediatrica : revista Chilena de pediatría 2023-04, Vol.94 (2), p.246
Main Authors: Ospina-Henao, Sebastián, Torres, Juan Pablo, Brea, José, Ávila-Agüero, María L
Format: Article
Language:eng ; spa
Subjects:
Carrier State - epidemiology
Carrier State - microbiology
Child
COVID-19 - epidemiology
COVID-19 - prevention & control
Humans
Pandemics
Pediatrics
Pneumococcal Infections - epidemiology
Pneumococcal Infections - microbiology
Pneumococcal Infections - prevention & control
Pneumococcal Vaccines - therapeutic use
Public Health
Streptococcus pneumoniae
Vaccines, Conjugate
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Streptococcus pneumoniae (also known as pneumococcus) is part of the natural bacterial flora of the nasal and pharyngeal mucosa, colonizes mainly the nasopharynx, and causes this carriage to precede pneumococcal disease, thus becoming the main source of propagation among people, especially in children. Since 1983, when the first 23-component anti-pneumococcal vaccine was authorized, different conjugated vaccines have been developed according to the circulating serotypes that cause invasive pneumococcal diseases (IPD), reducing the incidence and mortality of these diseases considerably. In November 2021, a group of experts held a virtual meeting to update and analyze the impact that pneumococcal vaccines have generated on the countries' public health, especially during the COVID-19 pandemic. The recommendations that emerged included the need to look for alternatives in serotype-independent vaccines after the introduction of pneumococcal conjugate vaccines (PCV) in the national immunization schedules, as well as to strengthen the surveillance of serotypes, focusing on those not included in the current vaccines. The objective of this report is to communicate the conclusions of the group of experts that in November 2021 analyzed the impact of pneumococcal vaccines on public health in the countries, in order to generate recommendations applicable in Latin America.
ISSN:2452-6053
DOI:10.32641/andespediatr.v94i2.4358